Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia

Division of Hematology, Department of Internal Medicine, Basel University Hospital, Basel

Hematology, Luzern Kantonsspital, Lucerne

Oncology Institute of Southern Switzerland, Bellinzona

Clinica Luganese Moncucco, Lugano

Ospedale San Raffaele, Milan

Dipartimento di Ematologia, Niguarda Cancer Center, Ospedale Niguarda, Milan

Ematologia, Ospedale di Circolo e Fondazione Macchi, Varese

Divisione di Ematologia, Universita' del Piemonte Orientale, Novara

Onco Ematologia Clinico Sperimentale, I.R.C.C.S. Centro di Riferimento Oncologico, Aviano

"Clinica Ematologica, Centro Trapianti e Terapie Cellulari Carlo Melzi", Udine

Department of Medical and Surgical Sciences, section of Hematology, Modena

Institute of Hematology, Catholic University S. Cuore, Roma

Department of Haematology, Tor Vergata Hospital, Rome